Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-Conotoxin VC 1.1
- Development stage
- Unknown
- Lead developer
- PolyNovo
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
alpha-Conotoxin VC 1.1 is a synthetic, disulfide-rich peptide derived from the venom of the marine cone snail *Conus victoriae*. It belongs to the α-conotoxins, a subclass of conotoxins characterized by their cysteine framework and loop structure (4/7 α-conotoxin). The peptide specifically blocks certain subtypes of neuronal nicotinic acetylcholine receptors (nAChRs), particularly those containing the α3 subunit in the peripheral nervous system[5][6]. Additionally, it acts as an agonist at GABA-B receptors, leading to inhibition of voltage-gated calcium channels (notably CaV2.2 and CaV2.3), which reduces neuronal excitability and nociceptive signaling[3]. These mechanisms underlie its antinociceptive effects observed in animal models of neuropathic pain and chronic visceral pain[3][5]. The drug was developed as an experimental analgesic for neuropathic pain but was discontinued after clinical trials due to reduced potency at human nAChR targets[7].
- Other names
- .ALPHA.-CONOTOXIN VC 1.1Vc1.1 alpha-conotoxinVc-1.1 alpha-conotoxinVc 1.1 alpha-conotoxin
02
Targets
CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)α9α10 nAChR (α9α10 nicotinic receptor)CHRNA3 (nAChR α3 subunit)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on alpha-Conotoxin VC 1.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-Conotoxin VC 1.1.